But one active clinical trial, registered as NCT07092605 on ClinicalTrials.gov, is now specifically studying the effectiveness of microdosed GLP-1 receptor agonists for improving health and quality of life in patients who do not meet traditional prescribing criteria
The primary side effects are gastrointestinal symptoms including bloating, abdominal discomfort, loose stools, and diarrhoea, particularly at doses exceeding 0.40.5 grams per kilogram of body weight per day
Mike Haney: How much do you care about the muscle loss side
Particles: Floating specks or sediment indicate peptide breakdown and aggregation
This article lives in the PlexusDx Education Hub, our library on GLP-1 therapies, weight management protocols, and the genetic variables behind every metabolic decision